RT @nataliagandur: 🌟📢 @ASCO #GU25 | PORTOS in Prostate Cancer🌟 👥 Presented by Shuang (George) Zhao, MD @OncoAlert 🔬 PORTOS (Prostate Cance…

RT @bavilima: Day 1️⃣ @ASCO #GU25 #ProstateCancer @neerajaiims TALAPRO-2 ✨ ▶️Talazoparib+Enza 1L mCRPC ▶️ OS benefit in unselected pts👉8…

Start of #GU25 - excited to be part of it! Looking forward to seeing all the new #prostatecancer data today and meet with our collaborators!

Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series out on European Urology Oncology Multicenter retrospective study evaluated stereotactic body radiation therapy (SBRT)☢️ as a noninvasive treatment for inoperable primary renal cell carcinoma ( #RCC ). Involving 144 patients treated across 16 centers in Australia, France, Italy, and the Netherlands between 2008 and 2020, the study found an excellent local control (LC) rate of 98% at 1 year and 96% at 5 years. The median overall survival (OS) was 58 months, and the cumulative incidence of cancer-related deaths was 8% at 5 years. Toxicities were mostly mild (49% experienced toxicity, with only 1% experiencing grade 4 events such as dialysis). Renal function was well preserved, with a median estimated glomerular filtration rate (eGFR) loss of –7 ml/min at the last follow-up. These results suggest SBRT is an effective and well-tolerated option for inoperable RCC patients. #KidneyCancer @dr_alimuhammad @UliSchick @stephane_supiot @CiroFranzese1 @MartaScorsetti @DrAndreiFodor @NicosiaMd @alongi_filippo @MarioTerlizziFR @PBlanchardMD @mcmbarthoulot @_ShankarSiva @David__Pasquier @OncoAlert 🚨

RT @nataliagandur: 📢 @ASCO #GU25 | Abstract #659 🔬 NIAGARA: Perioperative Durvalumab + NAC improves survival & pCR in MIBC! @tompowles1 @Ma…

RT @nataliagandur: 📢 @ASCO #GU25 | Abstract #309 🔬 RP vs. RT in High-Risk Prostate Cancer (HR-PCa): Which is better? @Soum_Roy_RadOnc @DrSp…

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy out on JCI Insight Study explores the role of circulating immune markers🎯 in predicting response to immune checkpoint inhibitors (ICIs) in patients with metastatic clear cell renal cell carcinoma. In a cohort of 33 patients, baseline levels of classical monocyte subsets (CD14+ CD16-) and seven cytokines (IL-12/23 p40, MIP-1a, MIP-1b, VCAM-1, ICAM-1, IL-8, and TNF-alpha) were significantly higher in responders compared to non-responders. Additionally, dynamic changes in TARC, PlGF, and VEGF correlated with treatment response. #kidneyCancer Findings suggest that macrophage activation and the innate immune response play crucial roles in ICI efficacy, offering potential biomarkers for predicting treatment outcomes. @_joycehwang @andyzwang @AarmstrongDuke @MRHarrisonMD @Daniel_J_George @TiansterZhang

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer out on Breast Cancer Research and Treatment This early-terminated trial investigated whether mifepristone💊a glucocorticoid receptor (GR) antagonist, could enhance the efficacy of nab-paclitaxel in patients with advanced triple-negative #BreastCancer TNBC. Of the planned 64 patients, 29 were enrolled, randomized to receive nab-paclitaxel with or without mifepristone. The study found NO🚫 improvement in progression-free survival (PFS) or response rate with the addition of mifepristone. Although there was a trend towards improved overall survival, it was driven by a single long-term responder. The combination treatment led to higher rates of grade 3 neutropenia, while other toxicities were comparable between groups. Increased GR expression did not correlate with response. @MargariteMatos1 @MurtuzaRampurwa @olwenhahn @fredhow @RitaNandaMD @KamarajuSailaja @suzanneconzenmd @ReasorErica

RT @APCCC_Lugano: Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-a…

RT @_ShankarSiva: ❓Wondering whats new in stage IV #cancer? Incidence of mets in #breastcancer or #prostatecancer? Role of 🧬genomics, ☢️PET…

With #ascoGU25 coming up, we are already looking forward to the short webinar of @PGrivasMDPhD and @BertrandTOMBAL translating the new data on advanced #prostatecancer into clinical practice! ➡️Register now: @OncoAlert

RT @nataliagandur: 🌟📢 @ASCO #GU25 | Abstract #308 🔬 PORTOS predicts response to RT dose escalation (DE) in prostate cancer.🌟 @a_dalpra 📊 K…

RT @neerajaiims: Ab#20 @ASCO #GU25 by #DavidFisher👉�Meta-analysis of key trials in mHSPC #prostatecancer👉ARPI benefi…

The significance of isolated de novo red patches in the bladder in patients referred with suspected urinary tract cancer: IDENTIFY study Study assessed the malignancy rate in patients with isolated de novo red patches in the bladder and identified risk factors to better guide biopsy decisions. Using data from 1110 patients, 41.5% underwent biopsies, with a malignancy rate of 12.8%, which was higher in suspicious-looking patches (19.1%) compared to non-suspicious ones (2.81%). Key risk factors for #BladderCancer included older age, smoking history, and the appearance of a suspicious patch. Although clinical experience did not significantly alter malignancy rates between suspicious and non-suspicious patches, the study highlights the need for more selective biopsy approaches, especially considering patient age and risk factors, to avoid unnecessary procedures. @carme_mir1 @Luca_Afferi @gehi87 @JGomezRivas @veerukasi @NICOLETTIRosse1 @peterchiu_uro @MRoupret @DrShariat @jteoh_hk @LAUrology_NL @OncoAlert 🚨

Annual versus less frequent mammographic surveillance in people with #BreastCancer aged 50 years and older in the UK (Mammo-50) The Mammo-5⃣0⃣ trial, a multicenter, phase 3 randomized study conducted across 114 NHS hospitals in the UK, evaluated whether less frequent mammography (2-yearly after conservation surgery and 3-yearly after mastectomy) is non-inferior to annual mammograms in terms of breast cancer-specific survival in women aged 50 years or older who are recurrence-free 3 years post curative surgery. With 5235 women randomly assigned and a median follow-up of 5.7 years, the study found no significant difference in 5-year breast cancer-specific survival between the annual and less frequent mammography groups (98.1% vs. 98.3%), demonstrating non-inferiority. Recurrence-free interval, overall survival, and event detection through emergency admissions or symptomatic referrals were also comparable, supporting the consideration of less frequent mammography for this population. @drpeterdonnelly @ProfAMThompson @DrSueHartup @PeterHall001 @OncoAlert 🚨

Hans Wildiers setting the scene on emerging treatments, ET resistance and redefining HER2-status. Watch our webinar on the management of HR+ HER2- metastatic #BreastCancer ➡️ register for free at With @E_de_Azambuja @EtienneB66 Cristina Saura Manich and Valentina Guarneri @OncoAlert

Interested to see how @E_de_Azambuja would treat this and other HR+ HER2- metastatic #BreastCancer patients? Our free case-based webinar is available on demand! Register at With Valentina Guarneri, Cristina Saura Manich, Hans Wildiers and Etienne Brain

Now available on demand❗️ Register at for free to access this and other webinars! With @E_de_Azambuja @EtienneB66 Cristina Saura, Valentina Guarneri and Hans Wildiers #BreastCancer @OncoAlert

Next Wednesday at 19:00 hrs CET: free and EACCME-accredited webinar on the management of HR+ HER2- metastatic breast cancer. ❗️Join our expert panel and register here: @HansWildiers @CristinaSaura3 @EtienneB66 @E_de_Azambuja

RT @E_de_Azambuja: Join us in this webinar "optimising the managment of HR+ HER2- metastatic breast cancer". An international expert panel…